BELL.L

Belluscura Plc
Belluscura PLC - Director/PDMR Shareholding
4th July 2024, 12:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2083V
Belluscura PLC
04 July 2024
 

4 July 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company")

 

Director/PDMR Shareholding

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that on 3 July 2024, David Poutney, Non-Executive Director of the Company, sold 4,350,000 ordinary shares of 1 penny each ("Ordinary Shares") held in his own name, and 3,800,000 Ordinary Shares were acquired by his self-invested pension plan ("SIPP") with the balance of 550,000 Ordinary Shares being acquired by his wife's, Vivienne Poutney and a person closely associated, SIPP.

Following this transfer, Mr Poutney, and his persons closely associated, remain interested in a total of 14,255,731 Ordinary Shares in the Company, representing 8.53 per cent. of the Company's issued Ordinary Share capital.

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman
Robert Rauker, Chief Executive Officer

 

 

 

SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

 

 

 

Dowgate Capital Limited

Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Nicholas Chambers

 

 

 

MHP Group

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

Katie Hunt / Matthew Taylor

 

 

About Belluscura plc (https://belluscura.com/)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Poutney (PDMR)

2

Reason for notification

a)

Position / status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.01 each in Belluscura plc

ISIN: GB00BD3B8Z11

b)

Nature of the transaction

(i)            Sale of shares

(ii)           Purchase of shares in SIPP

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

(i)            Sale: 16p

 

(ii)           Purchase: 16p

4,350,000

 

3,800,000

 

 

 

 

 

d)

Aggregated information

n/a

e)

Date of the transaction

3 July 2024

f)

Place of the transaction

London Stock Exchange

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Vivienne Poutney

2

Reason for notification

a)

Position / status

Person closely associated of David Poutney

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.01 each in Belluscura plc

ISIN: GB00BD3B8Z11

b)

Nature of the transaction

Purchase of shares in SIPP

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

16p

550,000

 

 

 

 

 

d)

Aggregated information

n/a

e)

Date of the transaction

3 July 2024

f)

Place of the transaction

London Stock Exchange

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHRIMTTMTTMBII]]>
TwitterFacebookLinkedIn